フィルター
6 件の結果が “3569” で取得されました
並べ替える:
アルファベット順（A-Z）
ベストセラー
huIL6
製品ID :
C001605
系統:
C57BL/6NCya
状況:
説明:
Interleukin-6 (IL-6) is a cytokine that plays a crucial role in inflammation and B cell maturation. It is primarily produced and secreted into the serum at sites of acute and chronic inflammation, inducing inflammatory responses through the interleukin-6 receptor alpha (IL-6Rα). Upon binding to IL-6Rα, IL-6 interacts with two GP130 molecules to form a hexameric complex in a 2:2:2 configuration. This receptor complex formation recruits tyrosine kinases from the Janus kinase family (JAK1, JAK2, and TYK2), which phosphorylate tyrosine sites within the intracellular domain of GP130, leading to the activation of signaling cascades. IL-6 has a broad impact on both immune and non-immune cells. In CD4+ T helper (Th) cells, IL-6 drives the differentiation of activated naïve Th cells into IL-17 and IL-22 expressing Th17 and Th22 cells, which are crucial for anti-bacterial and anti-fungal defense. Conversely, IL-6 inhibits the differentiation of CD4+ T regulatory cells, which play a key role in restraining inflammatory responses. In hepatocytes, IL-6 induces the expression of inflammation-induced acute phase proteins, including C-reactive protein (CRP) [1]. IL-6 is a pleiotropic cytokine associated with various diseases, including diabetes and systemic juvenile idiopathic arthritis. IL-6 signatures, partially based on the activity of STAT1 and STAT3, are indicators of prognosis or therapeutic response in patients with autoimmune diseases or cancer. Its role as a target in cancer immunotherapy and autoimmune diseases has attracted widespread attention [2-4].
The huIL6 mouse is an Il6 gene humanized model, in which the endogenous Il6 gene sequence in mice is replaced in situ with the human IL6 gene sequence. This model can be used in researching autoimmune diseases, inflammation-related diseases, cancer, and infectious diseases. It is also useful for the development, screening, and evaluation of IL6-targeted drugs.
Interleukin-6 (IL-6) is a cytokine that plays a crucial role in inflammation and B cell maturation. It is primarily produced and secreted into the serum at sites of acute and chronic inflammation, inducing inflammatory responses through the interleukin-6 receptor alpha (IL-6Rα). Upon binding to IL-6Rα, IL-6 interacts with two GP130 molecules to form a hexameric complex in a 2:2:2 configuration. This receptor complex formation recruits tyrosine kinases from the Janus kinase family (JAK1, JAK2, and TYK2), which phosphorylate tyrosine sites within the intracellular domain of GP130, leading to the activation of signaling cascades. IL-6 has a broad impact on both immune and non-immune cells. In CD4+ T helper (Th) cells, IL-6 drives the differentiation of activated naïve Th cells into IL-17 and IL-22 expressing Th17 and Th22 cells, which are crucial for anti-bacterial and anti-fungal defense. Conversely, IL-6 inhibits the differentiation of CD4+ T regulatory cells, which play a key role in restraining inflammatory responses. In hepatocytes, IL-6 induces the expression of inflammation-induced acute phase proteins, including C-reactive protein (CRP) [1]. IL-6 is a pleiotropic cytokine associated with various diseases, including diabetes and systemic juvenile idiopathic arthritis. IL-6 signatures, partially based on the activity of STAT1 and STAT3, are indicators of prognosis or therapeutic response in patients with autoimmune diseases or cancer. Its role as a target in cancer immunotherapy and autoimmune diseases has attracted widespread attention [2-4].
The huIL6 mouse is an Il6 gene humanized model, in which the endogenous Il6 gene sequence in mice is replaced in situ with the human IL6 gene sequence. This model can be used in researching autoimmune diseases, inflammation-related diseases, cancer, and infectious diseases. It is also useful for the development, screening, and evaluation of IL6-targeted drugs.
huIL6/hIL6RA
製品ID :
C001607
系統:
C57BL/6NCya
状況:
説明:
Interleukin-6 (IL-6) is a cytokine that plays a crucial role in inflammation and B cell maturation. It is primarily produced and secreted into the serum at sites of acute and chronic inflammation, inducing inflammatory responses through the interleukin-6 receptor alpha (IL-6Rα). The IL6RA (IL6R, also known as CD126) gene encodes a subunit of the interleukin-6 (IL-6) receptor complex. The IL-6 receptor is a protein complex composed of the IL6RA protein and the interleukin-6 signal transducer (IL6ST/GP130/IL6-beta). This receptor subunit is shared by many other cytokines. The expression of IL-6R is primarily restricted to hepatocytes, leukocytes, and megakaryocytes. Upon binding to IL-6Rα, IL-6 interacts with two GP130 molecules to form a hexameric complex in a 2:2:2 configuration [1]. Once the IL-6 receptor complex is activated, multiple downstream events allow IL-6 to mediate its diverse effects. These include the pathways of the GTPase Ras and its effector Raf, the mitogen-activated protein kinase cascade that controls cellular proliferation and differentiation, and the pathways involving tyrosine kinases of the Jak family and transcription factors of the STAT family [2]. IL-6 has a broad impact on both immune and non-immune cells. In CD4+ T helper (Th) cells, IL-6 drives the differentiation of activated naïve Th cells into IL-17 and IL-22 expressing Th17 and Th22 cells, which are crucial for anti-bacterial and anti-fungal defense. Conversely, IL-6 inhibits the differentiation of CD4+ T regulatory cells, which play a key role in restraining inflammatory responses. In hepatocytes, IL-6 induces the expression of inflammation-induced acute phase proteins, including C-reactive protein (CRP) [1]. Research has shown that the IL-6 pathway is crucial for maintaining homeostasis and is involved in the dysregulation seen in many diseases. Antibody drugs targeting the IL-6/IL-6 receptor signaling pathway have become innovative therapies for autoimmune diseases and cancers [2-5].
The huIL6/hIL6RA mice are a double-gene humanized model obtained by breeding huIL6 mice (Catalog No. C001605) with hIL6RA mice (Catalog No. C001606). This model can be used in researching autoimmune diseases, inflammation-related diseases, cancer, and infectious diseases. It is also useful for the development, screening, and evaluation of IL6/IL6RA-targeted drugs.
Interleukin-6 (IL-6) is a cytokine that plays a crucial role in inflammation and B cell maturation. It is primarily produced and secreted into the serum at sites of acute and chronic inflammation, inducing inflammatory responses through the interleukin-6 receptor alpha (IL-6Rα). The IL6RA (IL6R, also known as CD126) gene encodes a subunit of the interleukin-6 (IL-6) receptor complex. The IL-6 receptor is a protein complex composed of the IL6RA protein and the interleukin-6 signal transducer (IL6ST/GP130/IL6-beta). This receptor subunit is shared by many other cytokines. The expression of IL-6R is primarily restricted to hepatocytes, leukocytes, and megakaryocytes. Upon binding to IL-6Rα, IL-6 interacts with two GP130 molecules to form a hexameric complex in a 2:2:2 configuration [1]. Once the IL-6 receptor complex is activated, multiple downstream events allow IL-6 to mediate its diverse effects. These include the pathways of the GTPase Ras and its effector Raf, the mitogen-activated protein kinase cascade that controls cellular proliferation and differentiation, and the pathways involving tyrosine kinases of the Jak family and transcription factors of the STAT family [2]. IL-6 has a broad impact on both immune and non-immune cells. In CD4+ T helper (Th) cells, IL-6 drives the differentiation of activated naïve Th cells into IL-17 and IL-22 expressing Th17 and Th22 cells, which are crucial for anti-bacterial and anti-fungal defense. Conversely, IL-6 inhibits the differentiation of CD4+ T regulatory cells, which play a key role in restraining inflammatory responses. In hepatocytes, IL-6 induces the expression of inflammation-induced acute phase proteins, including C-reactive protein (CRP) [1]. Research has shown that the IL-6 pathway is crucial for maintaining homeostasis and is involved in the dysregulation seen in many diseases. Antibody drugs targeting the IL-6/IL-6 receptor signaling pathway have become innovative therapies for autoimmune diseases and cancers [2-5].
The huIL6/hIL6RA mice are a double-gene humanized model obtained by breeding huIL6 mice (Catalog No. C001605) with hIL6RA mice (Catalog No. C001606). This model can be used in researching autoimmune diseases, inflammation-related diseases, cancer, and infectious diseases. It is also useful for the development, screening, and evaluation of IL6/IL6RA-targeted drugs.
NKG-hIL6
製品ID :
I001176
系統:
NKG
状況:
説明:
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, exhibits reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.
In immunology research, direct studies on mice may not fully represent the human immune system due to physiological and immune system differences. However, by transplanting human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) into immunodeficient mice, we can partially or completely replace the mouse immune system with a human counterpart. This approach enables in vivo simulation of human immune system function, providing an effective model for studying human immunity. In practical human-mouse xenotransplantation, using standard immunodeficient mice for transplantation may lead to differences in transplant efficiency due to the absence of specific human growth factors and supportive stromal cells within the mouse. Genetically modifying immunodeficient mice through gene editing techniques is a common strategy to enhance xenotransplantation efficiency.
Interleukin-6 (IL-6) is a cytokine that plays a crucial role in inflammation and B cell maturation. It is primarily produced and secreted into the bloodstream at acute and chronic inflammatory sites. IL-6 induces transcriptional inflammatory responses through its receptor, IL6Rα. Research indicates that immunodeficient mice carrying the human IL6 gene effectively enhance the differentiation of human monocytes and macrophages during HSC reconstruction [1]. NKG-hIL6 mice were constructed by introducing the human IL6 gene into the genome of NKG mice. Compared to NKG mice, NKG-hIL6 mice can efficiently and rapidly rebuild human CD45+ leukocytes during HSC reconstruction. These mice are valuable for developing tumor immunotherapies and drug evaluations.
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, exhibits reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.
In immunology research, direct studies on mice may not fully represent the human immune system due to physiological and immune system differences. However, by transplanting human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) into immunodeficient mice, we can partially or completely replace the mouse immune system with a human counterpart. This approach enables in vivo simulation of human immune system function, providing an effective model for studying human immunity. In practical human-mouse xenotransplantation, using standard immunodeficient mice for transplantation may lead to differences in transplant efficiency due to the absence of specific human growth factors and supportive stromal cells within the mouse. Genetically modifying immunodeficient mice through gene editing techniques is a common strategy to enhance xenotransplantation efficiency.
Interleukin-6 (IL-6) is a cytokine that plays a crucial role in inflammation and B cell maturation. It is primarily produced and secreted into the bloodstream at acute and chronic inflammatory sites. IL-6 induces transcriptional inflammatory responses through its receptor, IL6Rα. Research indicates that immunodeficient mice carrying the human IL6 gene effectively enhance the differentiation of human monocytes and macrophages during HSC reconstruction [1]. NKG-hIL6 mice were constructed by introducing the human IL6 gene into the genome of NKG mice. Compared to NKG mice, NKG-hIL6 mice can efficiently and rapidly rebuild human CD45+ leukocytes during HSC reconstruction. These mice are valuable for developing tumor immunotherapies and drug evaluations.
Pcm1-KO
製品ID :
S-KO-03569
系統:
C57BL/6NCya
状況:
説明:
Pcm1 is located on chromosome 8 of mice. Nuclease Technology was used to design sgRNA; Pcm1 knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Pcm1 is located on chromosome 8 of mice. Nuclease Technology was used to design sgRNA; Pcm1 knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Mxd4-flox
製品ID :
S-CKO-03569
系統:
C57BL/6JCya
状況:
説明:
Mxd4 is located on chromosome 5 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Mxd4 conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Mxd4 is located on chromosome 5 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Mxd4 conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
NKG-SGM3/hIL6/Kit*V831M
製品ID :
C001695
系統:
NKG
状況:
説明:
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, has reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.
Interleukin-6 (IL-6) is a cytokine that plays a crucial role in inflammation and B cell maturation. It is primarily produced and secreted into the bloodstream at acute and chronic inflammatory sites. IL-6 induces transcriptional inflammatory responses through its receptor, IL6Rα. Research indicates that immunodeficient mice carrying the human IL6 gene effectively enhance the differentiation of human monocytes and macrophages during HSC reconstruction [1].
The KIT gene encodes a receptor tyrosine kinase (c-Kit or CD117) that is activated by its ligand, stem cell factor (SCF). Activation of this receptor triggers phosphorylation of a variety of downstream intracellular proteins, governing essential cellular processes such as proliferation, differentiation, migration, and apoptosis across numerous cell types. The KIT gene plays a pivotal role in hematopoiesis, stem cell maintenance, gametogenesis, melanogenesis, and the development and function of mast cells. Mutations in KIT are implicated in a range of pathologies, including gastrointestinal stromal tumors, mastocytosis, and acute myeloid leukemia. Importantly, immunodeficient mice harboring the KIT W41 mutation (V831M) have demonstrated the ability to undergo human HSC transplantation without the need for irradiation, while maintaining high rates of engraftment [2-3].
The SCF gene, also known as KITLG, encodes the receptor-type protein-tyrosine kinase KIT ligand. This gene is crucial for the development of germ cells and neurons during embryogenesis and plays a significant role in hematopoiesis. The GM-CSF gene, or CSF2, encodes a cytokine that orchestrates the production, differentiation, and function of granulocytes and macrophages. Meanwhile, the IL3 gene encodes a growth-promoting cytokine essential for the proliferation of various blood cell types, influencing cell growth, differentiation, and apoptosis. Research demonstrates that severe immunodeficient mice expressing human IL3, GM-CSF (CSF2), and SCF (KITLG) show markedly enhanced engraftment efficiency in the xenotransplantation of acute myeloid leukemia (AML) [4], supporting stable engraftment of myeloid lineages and regulatory T cell populations [5].
NKG-SGM3/hIL6/Kit*V831M mice are mouse models obtained by mating KIT W41 mutation (V831M) mouse models (Catalog Number: I001175) with IL6 humanized mouse models (Catalog Number: I001176) and IL3, KITLG and CSF2 triple humanized mouse models (Catalog Number: I001177). These mice express human IL6, IL3, KITLG, and CSF2 genomic sequences, as well as mouse KIT genomic sequences carrying the W41 mutation (V831M). This model is a valuable tool for immuno-oncology, immunology, and infectious disease research.
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, has reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.
Interleukin-6 (IL-6) is a cytokine that plays a crucial role in inflammation and B cell maturation. It is primarily produced and secreted into the bloodstream at acute and chronic inflammatory sites. IL-6 induces transcriptional inflammatory responses through its receptor, IL6Rα. Research indicates that immunodeficient mice carrying the human IL6 gene effectively enhance the differentiation of human monocytes and macrophages during HSC reconstruction [1].
The KIT gene encodes a receptor tyrosine kinase (c-Kit or CD117) that is activated by its ligand, stem cell factor (SCF). Activation of this receptor triggers phosphorylation of a variety of downstream intracellular proteins, governing essential cellular processes such as proliferation, differentiation, migration, and apoptosis across numerous cell types. The KIT gene plays a pivotal role in hematopoiesis, stem cell maintenance, gametogenesis, melanogenesis, and the development and function of mast cells. Mutations in KIT are implicated in a range of pathologies, including gastrointestinal stromal tumors, mastocytosis, and acute myeloid leukemia. Importantly, immunodeficient mice harboring the KIT W41 mutation (V831M) have demonstrated the ability to undergo human HSC transplantation without the need for irradiation, while maintaining high rates of engraftment [2-3].
The SCF gene, also known as KITLG, encodes the receptor-type protein-tyrosine kinase KIT ligand. This gene is crucial for the development of germ cells and neurons during embryogenesis and plays a significant role in hematopoiesis. The GM-CSF gene, or CSF2, encodes a cytokine that orchestrates the production, differentiation, and function of granulocytes and macrophages. Meanwhile, the IL3 gene encodes a growth-promoting cytokine essential for the proliferation of various blood cell types, influencing cell growth, differentiation, and apoptosis. Research demonstrates that severe immunodeficient mice expressing human IL3, GM-CSF (CSF2), and SCF (KITLG) show markedly enhanced engraftment efficiency in the xenotransplantation of acute myeloid leukemia (AML) [4], supporting stable engraftment of myeloid lineages and regulatory T cell populations [5].
NKG-SGM3/hIL6/Kit*V831M mice are mouse models obtained by mating KIT W41 mutation (V831M) mouse models (Catalog Number: I001175) with IL6 humanized mouse models (Catalog Number: I001176) and IL3, KITLG and CSF2 triple humanized mouse models (Catalog Number: I001177). These mice express human IL6, IL3, KITLG, and CSF2 genomic sequences, as well as mouse KIT genomic sequences carrying the W41 mutation (V831M). This model is a valuable tool for immuno-oncology, immunology, and infectious disease research.
Items: 1 to 6 of 6
1